본문 바로가기
bar_progress

Text Size

Close

Xperix "Aggressive M&A and Rapid Subsidiary Growth Ignite Full-Fledged Corporate Value Re-Evaluation Momentum"

Xperix "Aggressive M&A and Rapid Subsidiary Growth Ignite Full-Fledged Corporate Value Re-Evaluation Momentum"

Artificial intelligence (AI) solutions company Xperix announced on October 15 that it has secured a full-fledged corporate value re-evaluation momentum by strengthening its group fundamentals, driven by aggressive mergers and acquisitions (M&A) and explosive growth of its subsidiaries.


Since 2023, Xperix has accelerated the construction of its future growth portfolio and successfully transformed its group structure. The company established XCM, an advanced materials firm for AI infrastructure, acquired XPLUS, a lifestyle branding company, and Intellectual Discovery (ID), a global IP monetization specialist, through a series of strategic M&As, securing new growth engines. This strategic expansion resulted in the group’s total assets reaching 200 billion won and created a virtuous cycle that generates synergies across business divisions.


The core business of digital identity verification solutions continues to support aggressive expansion based on solid performance. In the first half of this year, sales grew by 28.4% compared to the same period last year, and the gross profit margin reached 55.7%, serving as a stable cash cow. The resulting cash flow and AI technology capabilities are fueling increased investment in new businesses.


The impact of M&A is also visible. Subsidiary Intellectual Discovery saw its sales surge by 451% in the first half of this year compared to the same period last year, emerging as a new growth axis for the group. XCM is securing mass production volumes from major clients and pursuing multiple joint development projects, aiming to achieve approximately 85.7 billion won in sales by 2029 and leading long-term growth.


In particular, the group’s next-generation growth engine-AI digital healthcare-is drawing attention. Xperix has begun developing the world’s first digital convergence medicine in partnership with Hanmi Pharmaceutical, combining a global blockbuster obesity treatment with digital technology. Targeting commercialization in 2027, this project is considered a key driver that will dramatically enhance the group’s future value.


A Xperix representative stated, “Over the past two years, our M&A activities were not just about expanding our size, but about designing an ‘intelligent growth ecosystem’ where each business unit is organically connected around AI. The combination of stable core businesses, new businesses already delivering results, and future businesses soon to be realized will trigger a virtuous cycle that simultaneously improves the group’s asset soundness and corporate value.”


© The Asia Business Daily(www.asiae.co.kr). All rights reserved.


Join us on social!

Top